Correction To Depomed Story (Jan. 15)
17 January 2015 - 6:56AM
Dow Jones News
"DepoMed to Buy U.S. Rights to Nucynta From J&J Unit" at
4:31 p.m. ET Thursday and the update at 5:49 p.m. ET incorrectly
linked the higher guidance to overall revenue instead of net
product sales. DepoMed had projected about $113 million to $117
million in 2014 product sales and overall revenue of about $232
million to $242 million.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024